NBP — NovaBridge Biosciences
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1778016 ·
Last close
$0.82
Market Cap
$95.10M
52W High
$5.19
52W Low
$0.75
ADV30
518,763
Next earnings
2026-08-20
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 231,542,000 | 190,637,000 | 30,438,000 |
| Dec 2025 | 0 | — | -72,900,000 | -30,787,000 | 260,522,000 | 210,632,000 | 29,581,000 |
| Sep 2025 | 0 | — | -8,989,000 | -6,828,000 | 277,410,000 | 228,064,000 | 18,495,000 |
| Jun 2025 | 0 | — | -7,114,000 | -5,504,000 | 206,708,000 | 165,404,000 | 9,975,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,757,000
Investing CF
$0
Financing CF
$57,725,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.12
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,370,176,000
Inventory
—
Receivables
$5,640,000
ST Investments
$210,000
EBIT TTM
$-94,269,000
Pretax Income TTM
$-88,340,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -94,269,000 | -46,269,000 | 260,522,000 | 29,581,000 | 230,941,000 | -20,597,000 |
| Dec 2024 | 0 | -51,426,000 | -22,230,000 | 212,680,000 | 11,520,000 | 201,160,000 | -52,669,000 |
| Dec 2023 | 632,000 | -48,976,000 | -207,729,000 | 368,922,000 | 126,338,000 | 242,584,000 | -72,697,000 |
| Dec 2022 | -1,551,000 | -53,078,000 | -371,053,000 | 590,446,132 | 168,678,417 | 421,767,716 | -49,582,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RTSN | Retension Pharmaceuticals, Inc. | $95.06M | $11.41 | — |
| ANIX | Anixa Biosciences Inc | $92.82M | $2.67 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $92.15M | $1.22 | — |
| HSTC | HST Global, Inc. | $99.00M | $0.70 | — |
| ADAG | Adagene Inc. | $99.37M | $1.48 | — |
News headlines (Yahoo Finance, 1h cache)
Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
2026-11-18 12:00 · Yahoo
NovaBridge Biosciences to Participate in Upcoming Investor Conferences
2026-11-09 12:00 · Yahoo
I-Mab Picks Givastomig Dose After Promising Gastric Cancer Data, Aligns With FDA
2026-11-03 05:12 · Yahoo
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
2026-10-28 11:00 · Yahoo
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
2026-10-25 11:00 · Yahoo
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
2026-10-20 11:00 · Yahoo
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
2026-10-13 11:00 · Yahoo
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
2026-10-08 20:05 · Yahoo
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
2026-09-08 11:00 · Yahoo
NovaBridge Biosciences to Participate in September Investor Conferences
2026-08-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.